Digital twins have transitioned from being a product engineering tool to a solution to evaluate business factors such as operations and supply chain.
The need for structured oversight is growing as companies expand their use of contract manufacturing.
There was a shift in M&A strategies, sharpening of the FTC's oversight, and AI's influence grew in the top companies.
Move away from seeing usability, manufacturing, and supply chain as downstream hurdles to be cleared at the end of a process.
Cost volatility, geographic realignment, accelerating technology adoption, and rising supplier performance expectations are converging.
Legal- and regulatory-defined security operations are great and keep us all safer, but we do need standards and processes.
Clinical data standards are a key component to further data harmonization and accelerate regulatory reviews.
When considering relocating to a U.S.-based supply partner, it’s important to evaluate all factors and costs that will be involved.
The most important takeaway from the 2026 MPO Top 30 report is not embedded in any one transaction but rather the pattern among the ranked firms.
The FDA's QMSR, effective as of Feb. 2, 2026, embodies a fundamental structural shift in how medical device manufacturers in the U.S. establish quality.
Metallurgical testing provide scientific evidence to support sound engineering decisions.
Collaboration with a full-service polymer compounder can help device manufacturers react quickly to supply chain challenges.
During the development of a medical product, the proper steps need to be taken so scaling can take place as needed to meet demand.
At the enterprise level, a unified digital foundation creates clarity where fragmentation once existed.
The next generation of wearables must recognize that healthspan is shaped by connected systems, not isolated metrics.
In the modern medtech environment, due diligence has evolved from a transaction process into a competitive advantage.
A look inside interventional cardiology and vascular medicine with Dr. Ethan Korngold, chief medical officer of Abbott’s Vascular business.
Adjusting design decisions later in the process to accommodate biocompatibility needs can be costly and time-consuming.
Here’s a closer look at the firms that came closest to making the list.
